Efficacy and Safety Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease: 12-Month Results From the PREVAIL VII Study.
Ebola virus disease
cataract surgery
uveitis, manual small incision cataract surgery
Journal
Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
28
08
2020
accepted:
30
11
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
29
6
2021
Statut:
epublish
Résumé
In survivors of Ebola virus disease (EVD), intraocular viral persistence raises questions about the timing and safety of cataract surgery. To the best of our knowledge, this is the first controlled study evaluating Ebola virus persistence and cataract surgery safety and outcomes in EVD survivors. Seropositive EVD survivors and seronegative controls with vision worse than 20/40 from cataract and without active intraocular inflammation were enrolled. Aqueous humor from survivors was tested with reverse transcription-polymerase chain reaction for Ebola viral RNA. Participants underwent manual small-incision cataract surgery and 1 year of follow-up examinations. Twenty-two eyes of 22 survivors and 12 eyes of eight controls underwent cataract surgery. All of the aqueous samples tested negative for Ebola viral RNA. Median visual acuity improved from 20/200 at baseline to 20/25 at 1 year in survivors and from count fingers to 20/50 in controls (overall, EVD survivors and controls demonstrated significant visual improvement from cataract surgery. The persistence of intraocular inflammation highlights the importance of follow-up. The absence of detectable intraocular Ebola viral RNA provides guidance regarding the safety of eye surgery in Ebola survivors. These findings demonstrate the safety and efficacy of cataract surgery in Ebola survivors and will inform ocular surgery guidelines in this population.
Identifiants
pubmed: 33520427
doi: 10.1167/tvst.10.1.32
pii: TVST-20-2998
pmc: PMC7838547
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32Subventions
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Organisme : NEI NIH HHS
ID : K23 EY030158
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029594
Pays : United States
Informations de copyright
Copyright 2021 The Authors.
Déclaration de conflit d'intérêts
Disclosure: A.O. Eghrari, None; J.G. Shantha, None; R.D. Ross, None; C. Van Ryn, None; I. Crozier, None; B. Hayek, None; D. Gradin, None; B. Roberts, None; S.G. Prakalapakorn, None; F. Amegashie, None; K. Nishant, None; G. Singh, None; R. Dolo, None; J. Fankhauser, None; B. Burkholder, None; J. Pettitt, None; R. Gross, None; T. Brady, None; B. Dighero-Kemp, None; C. Reilly, None; L. Hensley, None; E. Higgs, None; S. Yeh, None; R.J. Bishop, None
Références
EBioMedicine. 2018 Apr;30:217-224
pubmed: 29622497
Eye (Lond). 2008 Jan;22(1):8-12
pubmed: 16751754
J Infect Dis. 2017 Feb 15;215(4):547-553
pubmed: 28003349
MMWR Morb Mortal Wkly Rep. 2019 Dec 20;68(50):1162-1165
pubmed: 31856146
JAMA Netw Open. 2021 Jan 4;4(1):e2032216
pubmed: 33399856
Ophthalmologica. 2003 Nov-Dec;217(6):408-12
pubmed: 14573973
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
Ophthalmology. 2016 Dec;123(12):2626-2628.e2
pubmed: 27594198
N Engl J Med. 2019 Mar 7;380(10):924-934
pubmed: 30855742
Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Acta Ophthalmol. 2010 Jun;88(4):e102-6
pubmed: 20384591
J Cataract Refract Surg. 2012 Aug;38(8):1360-9
pubmed: 22814042
Br J Ophthalmol. 2005 Sep;89(9):1079-83
pubmed: 16113352